New hope for rare blood cancer patients who failed standard therapies
NCT ID NCT04262141
First seen Jan 09, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tests a drug called IMG-7289 in people with two rare blood cancers—essential thrombocythemia (ET) and polycythemia vera (PV)—that did not get better with standard treatments. The goal is to see if the drug can help control blood cell counts and reduce symptoms. The trial is for adults who have already tried at least one standard therapy without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.